Pharma Focus Europe

Creyon Bio and Cajal Neuroscience Enter Collaboration to Develop Oligonucleotide-Based Therapies for Neurodegenerative Conditions

Thursday, May 02, 2024

Creyon Bio, Inc. ("Creyon") and Cajal Neuroscience ("Cajal") have recently announced a collaborative effort to develop innovative treatments for neurodegenerative diseases. Creyon specializes in engineering Oligonucleotide-Based Medicines (OBMs), while Cajal focuses on utilizing genetics and human data to identify therapeutic targets for neurodegeneration.

In this partnership, Cajal will be responsible for identifying targets and mechanisms of action using its discovery platform, while Creyon will use its Creyon™ Platform to engineer therapeutic candidates with optimal pharmacological properties and minimal side effects. Cajal will handle validation and IND-enabling studies for the lead candidates.

Creyon Bio, emphasized the collaborative synergy between Cajal's target discovery capabilities and Creyon's engineering expertise, underlining their shared goal of developing effective therapies for neurodegenerative disorders.

Cajal Neuroscience, expressed their optimism about the potential of oligonucleotide therapeutics in treating neurodegenerative diseases, noting Creyon's significant contribution to advancing their targets.

The collaboration aims to expedite the development of much-needed treatments for neurodegenerative diseases by leveraging innovative target discovery and expert engineering capabilities.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024